Specialists of the domestic pharmaceutical company Farmak have developed and brought to market a drug for the treatment of acute (stroke) and chronic cerebrovascular disorders: Lira (citicoline). The new drug is produced in the form of a solution for injection in 1000 mg ampoules No. 5 and 500 mg ampoules No. 5.
Farmak is actively working in the sphere of treatment of cardiovascular diseases. In particular, much attention is given to ensure comprehensive effective and affordable treatment of acute and chronic cerebrovascular disorders. To achieve this objective, the company's specialists have developed and brought to market the drug product Lira (citicoline).
Lira is indicated in the acute phase of cerebrovascular disorders and for the treatment of cerebrovascular complications and sequelae; in craniocerebral traumas and their consequences, neurological disorders (cognitive, sensitive and motor) caused by degenerative and vascular cerebral disorders.
The course of treatment with the drug is 4-6 weeks.
Growth of the global economy and the related high business activity will lead to an increase in demand for business trips. This forecast has been published by the Global Business Travel Association (GBTA). According to The Uriadovy Kurier, pharmacists are the main business tourism consumers in Ukraine. Farmak follows the global trend Farmak comprehensively c...
JSC “Farmak” will launch Eco-School, the single educational Internet platform, based on methodological materials approved by the Ministry of Education and Science of Ukraine from the beginning of the academic year. Eco-School is about to cover the whole territory of Ukraine and is becoming online. Due to the new Internet platform launched by Farm...
At the end of June, the European database EudraGMDP has been replenished with new GMP certificates that were issued by the regulatory authority of Poland to JSC “Farmak” for 2 manufacturing sites and a new storage site put into operation in the beginning of 2019. The planned recertification of 2 manufacturing sites confirmed their compliance […]